Erowid References Database
Walkey LR, Tanguay RL, el-Guebaly N.
“Narrative Review of Cannabidiol as an Antipsychotic and Recommendations for Legal Regulations”.
Canadian Journal of Addiction. 2018 Sep;9(3):23-29.
This paper will review the effects of cannabidiol (CBD) in regards to psychosis and schizophrenia, and its purported treatment for psychosis.
A PubMed search was completed using terms: "Cannabidiol and Psychosis," for which 63 studies were found; "Cannabidiol and Schizophrenia," for which 65 studies were found; and "Cannabidiol and Psychotomimetic," for which 37 studies were found. Inclusion criteria included English-language articles published from 2000 to present (July 2016) for human studies only, leading to 7 clinical trials for review. Following this search, 2 additional papers published in 2018 were added for completeness, totaling 9 clinical trials.
There have been recent studies showing psychosis is secondary to the tetrahydrocannabinol (THC) in marijuana; more striking is that studies were found showing CBD may be protective and actually have antipsychotic properties equal in efficacy to atypical antipsychotics. THC and CBD seem to have opposite physiologic effects on endogenous anandamide levels and cannabinol receptor binding, the mechanism likely leading to CBD's antipsychotic effect.
Early evidence shows that CBD may be a novel and viable treatment for psychosis. This may have an effect on the regulation of CBD and THC percentages in regards to the prevention of early onset schizophrenia.
[ Cite HTML